Company
Headquarters: Gateshead, United Kingdom
Employees: 15
CEO: Mr. Gregory P. Madison
£104.6 Million
GBP as of Jan. 1, 2026
US$140.8 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £5.9 M |
| EBITDA | £-22,513,607 |
| Gross Profit TTM | £2.0 M |
| Profit Margin | 44.71% |
| Operating Margin | -266.29% |
| Quarterly Revenue Growth | 65.80% |
Shield Therapeutics plc has the following listings and related stock indices.
Stock: LSE: STX
Stock: FSX: 1JS
Stock: OTC: SHIEF